水肿临床试验市场－全球产业规模、份额、趋势、机会和预测，按阶段、参与者、申办者、类型、地区和竞争格局划分，2020-2030年预测

2024年全球水肿临床试验市场规模为11.9亿美元，预计2030年将以4.00%的复合年增长率成长至15.1亿美元。全球水肿临床试验市场专注于研究评估用于治疗水肿（即体内组织中液体异常积聚）的新型药物、疗法和医疗器材的安全性和有效性。

主要市场驱动因素

全球范围内与水肿相关的慢性疾病负担日益加重，是推动临床试验市场发展的主要动力。随着心臟衰竭、肾臟病和肝硬化等疾病盛行率的上升，水肿的併发率也显着增加。

主要市场挑战

进行全面的临床试验需要大量的资金投入，加上监管审批流程耗时较长，严重阻碍了全球水肿临床试验市场的成长。药物研发所需的巨额资金投入，涵盖从临床前研究到所有阶段人体试验的各个环节，也成为製药公司面临的一大障碍。

主要市场趋势

在水肿临床试验中，生物标记在个人化治疗的应用日益广泛，这是一个显着的趋势。这种方法透过识别可能对某种疗法产生反应的特定患者亚群，促进药物研发，从而提高试验效率和治疗效果。

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球水肿临床试验市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依阶段（第一阶段、第二阶段、第三阶段、第四阶段）
  • 依参与者（儿科、成人科、老年科）划分
  • 赞助商（製药公司、学术机构、政府机构）
  • 依类型（全身性水肿、局部性水肿）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美水肿临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲水肿临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区水肿临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲水肿临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲水肿临床试验市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球水肿临床试验市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• Otsuka Holdings Co. Ltd.
• Novartis AG
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Sanofi SA
• AstraZeneca plc
• Bristol Myers Squibb India Pvt. Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Edema Clinical Trials Market, valued at USD 1.19 Billion in 2024, is projected to experience a CAGR of 4.00% to reach USD 1.51 Billion by 2030. The Global Edema Clinical Trials Market focuses on research studies evaluating the safety and efficacy of novel drugs, therapies, and medical devices developed to manage edema, which involves the abnormal accumulation of fluid in body tissues.

Key Market Drivers

The rising global burden of edema-associated chronic diseases is a primary impetus for the clinical trials market. As the prevalence of conditions like heart failure, kidney disease, and liver cirrhosis escalates, the concurrent incidence of edema increases significantly. This expanding patient demographic urgently requires advanced therapeutic interventions. According to the World Health Organization (WHO), in a fact sheet updated May 2023, noncommunicable diseases (NCDs) accounted for 41 million deaths annually in 2021, representing 74% of all global deaths, with many NCDs directly contributing to edema.

Key Market Challenges

The considerable financial investment required for conducting comprehensive clinical trials, coupled with extended timelines for regulatory approvals, presents a substantial impediment to the growth of the Global Edema Clinical Trials Market. The extensive capital outlay necessary for drug development, encompassing preclinical research through all phases of human trials, acts as a significant barrier for pharmaceutical companies.

Key Market Trends

The increased use of biomarkers for personalized treatment is a significant trend in edema clinical trials. This approach enhances drug development by identifying specific patient subpopulations likely to respond to a therapy, thereby improving trial efficiency and therapeutic outcomes. For example, in April 2025, research identified choroidal thickness (CCT) as a crucial biomarker for diabetic macular edema, where normal CCTs correlated with better treatment responses to aflibercept.

Key Market Players

• Otsuka Holdings Co. Ltd.
• Novartis AG
• Genentech, Inc.
• Johnson & Johnson Services, Inc.
• Merck & Co., Inc.
• Sanofi S.A.
• AstraZeneca plc
• Bristol Myers Squibb India Pvt. Ltd.
• GlaxoSmithKline plc
• AbbVie Inc.

Report Scope:

In this report, the Global Edema Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Edema Clinical Trials Market, By Phase:

• Phase I
• Phase II
• Phase III
• Phase IV

Edema Clinical Trials Market, By Participants:

• Pediatrics
• Adults
• Geriatrics

Edema Clinical Trials Market, By Sponsor:

• Pharmaceutical Companies
• Academic Institutions
• Government Bodies

Edema Clinical Trials Market, By Type:

• Systemic Edema
• Localized Edema

Edema Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Edema Clinical Trials Market.

Available Customizations:

Global Edema Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Edema Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Participants (Pediatrics, Adults, Geriatrics)
  • 5.2.3. By Sponsor (Pharmaceutical Companies, Academic Institutions, Government Bodies)
  • 5.2.4. By Type (Systemic Edema, Localized Edema)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Edema Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Participants
  • 6.2.3. By Sponsor
  • 6.2.4. By Type
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Edema Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Participants
      • 6.3.1.2.3. By Sponsor
      • 6.3.1.2.4. By Type
  • 6.3.2. Canada Edema Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Participants
      • 6.3.2.2.3. By Sponsor
      • 6.3.2.2.4. By Type
  • 6.3.3. Mexico Edema Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Participants
      • 6.3.3.2.3. By Sponsor
      • 6.3.3.2.4. By Type

7. Europe Edema Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Participants
  • 7.2.3. By Sponsor
  • 7.2.4. By Type
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Edema Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Participants
      • 7.3.1.2.3. By Sponsor
      • 7.3.1.2.4. By Type
  • 7.3.2. France Edema Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Participants
      • 7.3.2.2.3. By Sponsor
      • 7.3.2.2.4. By Type
  • 7.3.3. United Kingdom Edema Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Participants
      • 7.3.3.2.3. By Sponsor
      • 7.3.3.2.4. By Type
  • 7.3.4. Italy Edema Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Participants
      • 7.3.4.2.3. By Sponsor
      • 7.3.4.2.4. By Type
  • 7.3.5. Spain Edema Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Participants
      • 7.3.5.2.3. By Sponsor
      • 7.3.5.2.4. By Type

8. Asia Pacific Edema Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Participants
  • 8.2.3. By Sponsor
  • 8.2.4. By Type
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Edema Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Participants
      • 8.3.1.2.3. By Sponsor
      • 8.3.1.2.4. By Type
  • 8.3.2. India Edema Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Participants
      • 8.3.2.2.3. By Sponsor
      • 8.3.2.2.4. By Type
  • 8.3.3. Japan Edema Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Participants
      • 8.3.3.2.3. By Sponsor
      • 8.3.3.2.4. By Type
  • 8.3.4. South Korea Edema Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Participants
      • 8.3.4.2.3. By Sponsor
      • 8.3.4.2.4. By Type
  • 8.3.5. Australia Edema Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Participants
      • 8.3.5.2.3. By Sponsor
      • 8.3.5.2.4. By Type

9. Middle East & Africa Edema Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Participants
  • 9.2.3. By Sponsor
  • 9.2.4. By Type
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Edema Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Participants
      • 9.3.1.2.3. By Sponsor
      • 9.3.1.2.4. By Type
  • 9.3.2. UAE Edema Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Participants
      • 9.3.2.2.3. By Sponsor
      • 9.3.2.2.4. By Type
  • 9.3.3. South Africa Edema Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Participants
      • 9.3.3.2.3. By Sponsor
      • 9.3.3.2.4. By Type

10. South America Edema Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Participants
  • 10.2.3. By Sponsor
  • 10.2.4. By Type
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Edema Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Participants
      • 10.3.1.2.3. By Sponsor
      • 10.3.1.2.4. By Type
  • 10.3.2. Colombia Edema Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Participants
      • 10.3.2.2.3. By Sponsor
      • 10.3.2.2.4. By Type
  • 10.3.3. Argentina Edema Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Participants
      • 10.3.3.2.3. By Sponsor
      • 10.3.3.2.4. By Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Edema Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Otsuka Holdings Co. Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Novartis AG
• 15.3. Genentech, Inc.
• 15.4. Johnson & Johnson Services, Inc.
• 15.5. Merck & Co., Inc.
• 15.6. Sanofi S.A.
• 15.7. AstraZeneca plc
• 15.8. Bristol Myers Squibb India Pvt. Ltd.
• 15.9. GlaxoSmithKline plc
• 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer